ProTgen Canada Inc.
ProTgen Canada Inc. is a Toronto-based, clinical-stage biotechnology company developing first-in-class targeted Notch activator-based cellular therapies and biologics to regenerate T-cell function, with a lead candidate, ProT-096, for refractory hematologic malignancies.
- Company typePrivate
- Founded2023
- HeadquartersToronto, Canada
- Headcount1–10
- GTM typeB2B
- OfferingServices
What ProTgen Canada Inc. does
ProTgen Canada Inc. is a clinical-stage biotechnology company headquartered in Toronto, Canada, founded in 2023. The company develops cellular therapies and biologics based on targeted Notch activators, an approach described as first-in-class and designed to regenerate T-cell function in patients with compromised immunity. The company's target indication set is anchored in refractory hematologic malignancies.
The pipeline is organized around two complementary platforms: an ex vivo cell therapy modality that produces personalized progenitor T-cell products, and an in vivo biologic modality leveraging the same underlying Notch biology. The lead clinical candidate, ProT-096, is a personalized progenitor T-cell therapy intended for patients with refractory hematologic malignancies, and the company is advancing it toward IND submission. The proprietary Notch-activator technology and the dual ex vivo / in vivo architecture constitute the core technical differentiators.
The business model is preclinical-to-early-clinical drug development. ProTgen has no marketed products and no product revenue; economics today are entirely on the R&D spend side, funded by a syndicate of strategic and venture investors that includes Boehringer Ingelheim, Eisai Innovation, SHERPA Healthcare Partners, FACIT, and Everjoy Fortune. Manufacturing risk for the autologous cell therapy is being addressed through a partnership with Cellares for automated production of ProT-096. Future revenue, if any, is expected to derive from out-licensing, partnership milestones, or eventual commercialization to specialty oncology centers treating refractory hematologic malignancy patients.
ProTgen Canada Inc. firmographics
Firmographics- Name
- ProTgen Canada Inc.
- Legal name
- ProTgen Inc.
- Website
- https://protgen.bio
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- ProTgen Canada Inc. is a Toronto-based, clinical-stage biotechnology company developing first-in-class targeted Notch activator-based cellular therapies and biologics to regenerate T-cell function, with a lead candidate, ProT-096, for refractory hematologic malignancies.
- Ownership category
- akta.pro rank
ProTgen Canada Inc. industry classification
Industry- Product category
- Cell Therapy and Immunotherapy Biotechnology
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)
- akta.pro secondary industries
- Cell Therapy Developers (Autologous) (HLAAABAA), Stem Cell–Based Regenerative Therapies (HLAAAGAA), Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL)
Keywords
Where ProTgen Canada Inc. is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Markets served
ProTgen Canada Inc. business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Cell Therapy Development and Commercialization: ProTgen is developing proprietary progenitor T-cell therapies including ProT-096 for hematologic malignancies. As a clinical-stage company, revenue generation is anticipated through eventual therapeutic product sales following regulatory approval and commercialization.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
ProTgen Canada Inc. product offering
Product offeringCore offering
ProTgen Canada Inc. is a clinical-stage biotechnology company that develops cellular therapies and biologics using targeted Notch activators to regenerate T-cell function and immune competence. Its lead clinical-stage product is ProT-096, a personalized progenitor T-cell therapy for refractory hematologic malignancies, delivered through two complementary platform approaches—an ex vivo cell therapy platform and a first-in-class in vivo biologic platform.
Product overview
ProTgen Canada Inc. is a biotechnology company developing targeted Notch activators to restore immune competence. The company's core product is ProT-096, a personalized progenitor T-cell therapy for refractory hematologic malignancies. The technology platform consists of two therapeutic approaches: an ex vivo cell therapy producing progenitor T cells for reinfusion, and a first-in-class in vivo biologic enabling direct thymus reactivation. The company's pipeline aims to rebuild adaptive immunity through targeted Notch activation, addressing the decline in T-cell diversity that occurs with age and disease.
Differentiator
Problem solved
Functional benefit
Products and services
- ProT-096 Personalized progenitor T-cell therapy in development by ProTgen Canada Inc. for the treatment of refractory hematologic malignancies, designed to regenerate T-cell function and immune competence using targeted Notch activators.
- Ex Vivo Cell Therapy Platform An ex vivo cell therapy platform from ProTgen that uses targeted Notch activators to generate engineered cell therapies ex vivo for regenerative immunology and oncology applications.
- In Vivo Biologic Platform A first-in-class in vivo biologic platform from ProTgen that delivers targeted Notch activators directly in vivo to regenerate T-cell function and immune competence in patients.
Quantifiable outcome
- Thymic output of naïve T cells declines by 1,000x over an 80-year lifespan, positioning thymus restoration as central to immune health
- +2 more outcomes
Companies that use ProTgen Canada Inc.
Customer profileSegments2 records
Ideal customer profiles2 records
ProTgen Canada Inc. technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
ProTgen Canada Inc. partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CellarescoreProTgen and Cellares partnered to automate manufacturing and quality control of ProT-096, ProTgen's personalized progenitor T-cell therapy for patients with refractory leukemia and hematologic malignancies. Cellares applies its fully automated Cell Shuttle and Cell Q platforms while providing regulatory expertise toward IND submission. The collaboration addresses manufacturing complexity that has historically hindered cell therapy development, enabling reproducible, scalable production required for clinical and eventual commercial scale.
Scale indicators2 records
Recent moves4 records
Expansion highlights4 records
ProTgen Canada Inc. competitors and assessment
Company assessmentDirect peers
- Cellectis: Clinical-stage allogeneic CAR-T developer using gene-edited iPSC-derived cell products. Comparable in cell fate engineering from stem cell sources and engineered T cell therapy format.
- Adaptimmune Therapeutics: Clinical-stage cell therapy company developing engineered TCR T cell therapies for hematologic malignancies and solid tumors. Closely comparable in target indication (refractory blood cancers) and personalized T cell therapy modality.
- Fate Therapeutics: Develops iPSC-derived NK and T cell therapies using induced pluripotent stem cells as starting material for off-the-shelf cell products. Comparable in cell fate engineering from stem cells, though focused on allogeneic rather than autologous formats.
- Century Therapeutics: iPSC-derived allogeneic cell therapies (including engineered NK and T cells) for cancer and autoimmune disease. Directly comparable in using stem cell platforms to generate immune cell products at scale.
- CRISPR Therapeutics: Gene-edited cell therapy developer (Casgevy, the first approved CRISPR therapy) for hemoglobinopathies and oncology. Comparable as a clinical-stage cell therapy company applying novel platform biology to immune cell engineering.
- Notch Therapeutics: Closest direct peer: develops engineered T cell therapies by controlling Notch signaling to drive T cell fate from stem cells. Highly comparable scientific mechanism, autologous cell therapy format, and pre-clinical/early-clinical stage.
- Precision BioSciences: Clinical-stage gene editing and cell therapy company developing allogeneic CAR-T and in vivo gene editing approaches. Comparable in cell therapy platform technology targeting hematologic malignancies.
- Allogene Therapeutics: Pioneering allogeneic CAR-T cell therapy developer with multiple clinical assets in hematologic malignancies. Comparable in engineered T cell therapy for refractory blood cancers, though focused on off-the-shelf rather than autologous products.
Emerging players
- Caribou Biosciences: Clinical-stage cell therapy company developing allogeneic CAR-T and CAR-NK products using CRISPR gene editing. Partial overlap as a cell therapy platform company but with a gene editing rather than Notch-activation mechanism.
Broad incumbents
- Bristol Myers Squibb (Celgene / Juno): Large incumbent biopharma with commercialized autologous CAR-T therapies (Breyanzi, Abecma) and a deep cell therapy pipeline. Comparable as a major player in personalized T cell therapies for hematologic malignancies, and a likely strategic acquirer of platform cell therapy companies.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
ProTgen Canada Inc. social profiles
Digital presenceProTgen Canada Inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
ProTgen Canada Inc. leadership team
Management profileNumber of profiles
Profiles2 records
ProTgen Canada Inc. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ProTgen Canada Inc. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ProTgen Canada Inc.
What does ProTgen Canada Inc. do?
ProTgen Canada Inc. is a clinical-stage biotechnology company that develops cellular therapies and biologics using targeted Notch activators to regenerate T-cell function and immune competence. Its lead clinical-stage product is ProT-096, a personalized progenitor T-cell therapy for refractory hematologic malignancies, delivered through two complementary platform approaches—an ex vivo cell therapy platform and a first-in-class in vivo biologic platform.
Is ProTgen Canada Inc. a public or private company?
ProTgen Canada Inc. is a private company. It is classified as venture growth investor backed and is currently operating.
When was ProTgen Canada Inc. founded?
ProTgen Canada Inc. was founded in 2023. It employs 1 to 10 people.
Where is ProTgen Canada Inc. based?
ProTgen Canada Inc. is headquartered in Toronto, Canada, in the North America region.
How does ProTgen Canada Inc. make money?
One revenue line is on record: cell Therapy Development and Commercialization.
Who are ProTgen Canada Inc.'s main competitors?
Direct peers on record are Cellectis, Adaptimmune Therapeutics, Fate Therapeutics, Century Therapeutics, CRISPR Therapeutics, Notch Therapeutics, Precision BioSciences and Allogene Therapeutics. Caribou Biosciences is listed as an emerging player. Bristol Myers Squibb (Celgene / Juno) is listed as a broad incumbent.
Does ProTgen Canada Inc. have an API?
No public API is recorded for ProTgen Canada Inc..
What industry is ProTgen Canada Inc. in?
ProTgen Canada Inc.'s product category is Cell Therapy and Immunotherapy Biotechnology. Its primary akta.pro industry code is HLAAABAE, Stem Cell Therapies (MSC/iPSC/HSC-derived), with a secondary code of HLAAABAA, Cell Therapy Developers (Autologous). Its NAICS code is 325414 and its SIC code is 2836.